DOI: 10.1182/blood.2025031828 ISSN: 0006-4971
Peginterferon alfa-2a, bictegravir-emtricitabine-tenofovir alafenamide, and venetoclax in adult T-cell leukemia/lymphoma
Ankit Tanwar, Nechama Dreyfus, Emma Cordover, Mimansa ., Kith Pradhan, Varun Gupta, Shikhar Sharma, Zixuan Tong, Latoya S Townsend, Surita Banerjee, Ioannis Mantzaris, Mendel Goldfinger, Nishi Shah, David Levitz, Aditi Shastri, Noah Kornblum, Dennis L Cooper, Anna Skwarska, Marina Konopleva, Ridhi Gupta, Alyssa de Castro, Margaret McCort, Yoram Puius, Beth McLellan, Lauren C Shapiro, Eric J Feldman, Kira Gritsman, Gregoire Lauvau, Xingxing Zang, Murali Janakiram, Amit Verma, Ali Bazarbachi, B.Hilda Ye, R. Alejandro SicaNorth American adult T-cell leukemia/lymphoma (NA-ATLL) has poor outcomes and limited therapeutic options. In a small case series, peginterferon-alfa-2a plus bictegravir/emtricitabine/tenofovir alafenamide, with selective venetoclax, suppressed HTLV-1, reduced circulating ATLL burden, supporting the prospective evaluation of this treatment modality.